Atara Biotherapeutics, Inc. (NASDAQ:ATRA)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued to clients and investors on Thursday. They presently have a $30.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 76.99% from the company’s current price.

A number of other equities research analysts have also recently issued reports on ATRA. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. ValuEngine cut shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective for the company in a report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $25.50.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) remained flat at $16.95 on Thursday. 24,542 shares of the company’s stock were exchanged. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $23.00. The firm’s market capitalization is $517.98 million. The stock has a 50-day moving average of $15.21 and a 200 day moving average of $15.65.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). Equities analysts predict that Atara Biotherapeutics will post ($3.89) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Jefferies Group LLC Reaffirms “Buy” Rating for Atara Biotherapeutics, Inc. (ATRA)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/05/jefferies-group-llc-reaffirms-buy-rating-for-atara-biotherapeutics-inc-atra.html.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 2,800 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $16.94, for a total transaction of $47,432.00. Following the completion of the sale, the chief executive officer now directly owns 731,859 shares in the company, valued at $12,397,691.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $15.54, for a total transaction of $68,376.00. Following the sale, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $11,464,899.18. The disclosure for this sale can be found here. Insiders sold 53,909 shares of company stock valued at $810,518 over the last quarter. 16.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in ATRA. Eagle Asset Management Inc. boosted its holdings in Atara Biotherapeutics by 17.8% during the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock valued at $20,901,000 after acquiring an additional 225,367 shares during the period. EcoR1 Capital LLC boosted its holdings in Atara Biotherapeutics by 101.5% during the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock valued at $8,935,000 after acquiring an additional 219,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Atara Biotherapeutics by 617.9% during the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock valued at $4,135,000 after acquiring an additional 173,184 shares during the period. Neuberger Berman Group LLC boosted its holdings in Atara Biotherapeutics by 15.7% during the second quarter. Neuberger Berman Group LLC now owns 967,980 shares of the biotechnology company’s stock valued at $13,552,000 after acquiring an additional 131,465 shares during the period. Finally, Camber Capital Management LLC bought a new stake in Atara Biotherapeutics during the first quarter valued at about $2,569,000. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.